Gapping down
In reaction to disappointing earnings/guidance: BLDP -6.6% (terminates license agreements with Azure; says 'The Company will not achieve its 2014 revenue and Adjusted EBITDA guidance').
Oil/gas related names showing early weakness (LINE / LNCO also weighing on select E&P names): LNCO -8.9% / LINE -7.2% (announces 2015 oil and gas capital budget; reduces annual distribution to $1.25 per unit from the previous level of $2.90; approves 2015 CapEx budget of $730 mln, down 53% y/y), BBEP -2.9%, STO -2.3%, SWN -2.2%, SDRL -2%, DVN -2%, SSL-1.5%, FI -1% (downgraded to Neutral from Buy at UBS ), FTI -1% (downgraded to Neutral from Buy at UBS ), BP -0.8%, RDS.A -0.8%.
Select Biotech/pharma names are modestly lower: PRGO -1.2%, SNY -1.1%, SHPG -1%,
Brazil ADRs are trading lower: PT -4.7%, VIV -2.9%, BBD -2.8%, PBR -2.7%, ABEV -2.7%, ITUB -2.3%, CZZ -1.9%, BSBR -1.8%, ELP -1.8%, VALE -1.6%,
Other news: MDXG -9.8% (filed a federal lawsuit against Organogenesis), HNR -6.1% (announces termination of agreement to sell remaining interests in Venezuela as a result of the failure to obtain approval of the transaction from the Government of the Bolivarian Republic of Venezuela by December 31, 2014), TGTX -5.4% ( files for $250 mln mixed securities shelf offering), NRX -3.4% (following 180%+ move on Wed), RYAAY -1.5% (disclosed it issued share capital that consists of ~1.387 mln ordinary shares of nominal value EUR 0.00635 each with voting rights), ABX -0.9% (reports that the Supreme Court of Chile has declined to consider an appeal of a lower court decision regarding sanctions imposed on the Pascua-Lama project), ARMH -0.9% and UL -0.8% (still checking).
Analyst comments: VIVO -1.6% (downgraded to Underperform from Mkt Perform at Raymond James), SWIR -0.5% (downgraded to Market Perform from Outperform at Northland Capital)
Oil/gas related names showing early weakness (LINE / LNCO also weighing on select E&P names): LNCO -8.9% / LINE -7.2% (announces 2015 oil and gas capital budget; reduces annual distribution to $1.25 per unit from the previous level of $2.90; approves 2015 CapEx budget of $730 mln, down 53% y/y), BBEP -2.9%, STO -2.3%, SWN -2.2%, SDRL -2%, DVN -2%, SSL-1.5%, FI -1% (downgraded to Neutral from Buy at UBS ), FTI -1% (downgraded to Neutral from Buy at UBS ), BP -0.8%, RDS.A -0.8%.
Select Biotech/pharma names are modestly lower: PRGO -1.2%, SNY -1.1%, SHPG -1%,
Brazil ADRs are trading lower: PT -4.7%, VIV -2.9%, BBD -2.8%, PBR -2.7%, ABEV -2.7%, ITUB -2.3%, CZZ -1.9%, BSBR -1.8%, ELP -1.8%, VALE -1.6%,
Other news: MDXG -9.8% (filed a federal lawsuit against Organogenesis), HNR -6.1% (announces termination of agreement to sell remaining interests in Venezuela as a result of the failure to obtain approval of the transaction from the Government of the Bolivarian Republic of Venezuela by December 31, 2014), TGTX -5.4% ( files for $250 mln mixed securities shelf offering), NRX -3.4% (following 180%+ move on Wed), RYAAY -1.5% (disclosed it issued share capital that consists of ~1.387 mln ordinary shares of nominal value EUR 0.00635 each with voting rights), ABX -0.9% (reports that the Supreme Court of Chile has declined to consider an appeal of a lower court decision regarding sanctions imposed on the Pascua-Lama project), ARMH -0.9% and UL -0.8% (still checking).
Analyst comments: VIVO -1.6% (downgraded to Underperform from Mkt Perform at Raymond James), SWIR -0.5% (downgraded to Market Perform from Outperform at Northland Capital)